[126] A Survey of 45 Biomarkers for Basal-Like Breast Cancer.

Jennifer R Choo, Dongxia Gao, Samuel Leung, Christine Chow, Sherman YH Lau, Jinjin Cheng, Torsten O Nielsen. University of British Columbia, Vancouver, Canada

Background: Basal-like breast cancer was originally identified by gene expression profiling, and it is associated with high-risk disease not responsive to available targeted therapies. Numerous biomarkers for basal-like breast cancer have been proposed. The following study performs a comprehensive immunohistochemical investigation of proposed biomarkers against a gene expression profile gold standard.
Design: Parallel analysis of 45 proposed basal-like biomarkers from literature and gene expression profile data was done on a breast cancer tissue microarray of cases (n = 122) where subtype was previously assigned by a PAM50 gene expression profile gold standard. Twenty-five of the 45 biomarkers were significantly associated with basal-like breast cancer (Table 1). Statistical analysis was performed using the Fisher's exact test corrected for multiple comparisons.
Results:

Table 1
Biomarker* Sensitivity Specificity Accuracy**
α-B-crystallin429273
Caveolin 2199865
Ck 142710067
Ck 17519275
Ck 5729082
Ck 5/6508772
c-Kit439675
Claudin 4667372
Cyclin E726677
EGFR419472
Fascin599377
IMP32510070
ki67945065
Moesin718482
Negative ER926772
Negative PR924657
Nestin559583
NGFR2210067
p16818280
p53558170
P-cadherin806172
PPH3945873
S100A9638275
Skp2627973
TRIM29728680
*Alphabetical order, adjusted p <.05; **Based on cases with complete data for all 45 biomarkers.

Biomarkers with a statistically non-significant association (adjusted p >.05) to basal-like breast cancer included: anilin, CAIX, caveolin 1, CD44, CD44v6, FABP7, FOXC1, negative Her2, Integrin β4, laminin5, loss of BRCA1, Met, negative p27, p63, p-glycoprotein, pS6rp, negative PTEN, SMAD4, VEGF and vimentin.
Conclusions: Nestin is the most accurate single biomarker for basal-like breast cancer among the 45 tested against a gene expression profile gold standard. These results can be used to build an optimal multi-biomarker panel, for which validation on an independent sample cohort would be required.
Category: Breast

Monday, February 28, 2011 9:30 AM

Poster Session I Stowell-Orbison/Surgical Pathology/Autopsy Awards Poster Session # 32, Monday Morning

 

Close Window